Latest Publications

@article{gavelova_reduction_2008,

title = {Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells.},

author = {Martina Gavelová and Jana Hladíková and Lenka Vildová and Romana Novotná and Jan Vondrácek and Pavel Krcmár and Miroslav Machala and Lenka Skálová},

doi = {10.1016/j.cbi.2008.07.011},

issn = {0009-2797},

year  = {2008},

date = {2008-10-01},

journal = {Chemico-biological interactions},

volume = {176},

number = {1},

pages = {9–18},

abstract = {In cancer cells, the drug-metabolizing enzymes may deactivate cytostatics, thus contributing to their survival. Moreover, the induction of these enzymes may also contribute to development of drug-resistance through acceleration of cytostatics deactivation. However, the principal metabolic pathways contributing to deactivation of many cytostatics still remain poorly defined. The main aims of the present study were: (i) to compare the reductive deactivation of cytostatic drugs doxorubicin (DOX) and oracin (ORC) in human breast cancer MCF-7 cells; (ii) to identify major enzyme(s) involved in the carbonyl reduction; and iii) to evaluate the activities and expression of selected carbonyl reducing enzymes in MCF-7 cells upon a short-term (48 h) exposure to either DOX or ORC. We found that MCF-7 cells were able to effectively metabolize both DOX and ORC through reduction of their carbonyl groups. The reduction of ORC was stereospecific, with a preferential formation of + enantiomer of dihydrooracin (DHO). The cytosolic carbonyl reductase CBR1 seemed to be a principal enzyme reducing both drugs, while cytosolic aldo-keto reductase AKR1C3 or microsomal reductases probably did not play important role in metabolism of either DOX or ORC. The exposure of MCF-7 cells to low (nanomolar) concentrations of DOX or ORC caused a significant elevation of reduction rates of both cytostatics, accompanied with an increase of CBR1 protein levels. Taken together, the present results seem to suggest that the accelerated metabolic deactivation of ORC or DOX might contribute to the survival of breast cancer cells during exposure to these cytostatics.},

note = {Place: Ireland},

keywords = {3-Hydroxysteroid Dehydrogenases/antagonists & inhibitors/genetics/metabolism, Alcohol Oxidoreductases/antagonists & inhibitors/*biosynthesis/genetics/metabolism, Aldehyde Reductase, Aldo-Keto Reductase Family 1 Member C3, Aldo-Keto Reductases, Biotransformation/drug effects, Blotting, Breast Neoplasms/*enzymology/genetics, Cell Line, Dose-Response Relationship, Doxorubicin/analogs & derivatives/chemistry/*metabolism/pharmacology, Drug, Enzyme Induction/drug effects, Enzyme Inhibitors/pharmacology, Ethanolamines/chemistry/*metabolism/pharmacology, Gene Expression Regulation, Humans, Hydroxyprostaglandin Dehydrogenases/antagonists & inhibitors/genetics/metabolism, Isoquinolines/chemistry/*metabolism/pharmacology, Kinetics, Messenger/genetics/metabolism, Methacrylates/pharmacology, Neoplastic/drug effects, Oxidation-Reduction/drug effects, Phenylpropionates/pharmacology, Quercetin/analogs & derivatives/pharmacology, RNA, Subcellular Fractions/drug effects/metabolism, Tumor, Western},

pubstate = {published},

tppubtype = {article}

}

@article{andrysik_aryl_2007,

title = {The aryl hydrocarbon receptor-dependent deregulation of cell cycle control induced by polycyclic aromatic hydrocarbons in rat liver epithelial cells.},

author = {Zdenek Andrysík and Jan Vondrácek and Miroslav Machala and Pavel Krcmár and Lenka Svihálková-Sindlerová and Anne Kranz and Carsten Weiss and Dagmar Faust and Alois Kozubík and Cornelia Dietrich},

doi = {10.1016/j.mrfmmm.2006.10.004},

issn = {0027-5107},

year  = {2007},

date = {2007-02-01},

journal = {Mutation research},

volume = {615},

number = {1-2},

pages = {87–97},

abstract = {Disruption of cell proliferation control by polycyclic aromatic hydrocarbons (PAHs) may contribute to their carcinogenicity. We investigated role of the aryl hydrocarbon receptor (AhR) in disruption of contact inhibition in rat liver epithelial WB-F344 'stem-like' cells, induced by the weakly mutagenic benz[a]anthracene (BaA), benzo[b]fluoranthene (BbF) and by the strongly mutagenic benzo[a]pyrene (BaP). There were significant differences between the effects of BaA and BbF, and those of the strongly genotoxic BaP. Both BaA and BbF increased percentage of cells entering S-phase and cell numbers, associated with an increased expression of Cyclin A and Cyclin A/cdk2 complex activity. Their effects were significantly reduced in cells expressing a dominant-negative AhR mutant (dnAhR). Roscovitine, a chemical inhibitor of cdk2, abolished the induction of cell proliferation by BbF. However, neither BaA nor BbF modulated expression of the principal cdk inhibitor involved in maintenance of contact inhibition, p27(Kip1), or pRb phosphorylation. The strongly mutagenic BaP induced apoptosis, a decrease in total cell numbers and significantly higher percentage of cells entering S-phase than either BaA or BbF. Given that BaP induced high levels of Cyclin A/cdk2 activity, downregulation of p27(Kip1) and hyperphosphorylation of pRb, the accumulation of cells in S-phase was probably due to cell proliferation, although S-phase arrest due to blocked replication forks can not be excluded. Both types of effects of BaP were significantly attenuated in dnAhR cells. Transfection of WB-F344 cells with siRNA targeted against AhR decreased induction of Cyclin A induced by BbF or BaP, further supporting the role of AhR in proliferative effects of PAHs. This suggest that activation of AhR plays a significant role both in disruption of contact inhibition by weakly mutagenic PAHs and in genotoxic effects of BaP possibly leading to enhanced cell proliferation. Thus, PAHs may increase proliferative rate and the likelihood of fixation of mutations.},

note = {Place: Netherlands},

keywords = {Animals, Apoptosis/drug effects, Aryl Hydrocarbon/antagonists & inhibitors/genetics/*metabolism, Base Sequence, Benz(a)Anthracenes/toxicity, Benzo(a)pyrene/toxicity, Cell Cycle Proteins/metabolism, Cell Cycle/*drug effects/*physiology, Cell Line, Cell Proliferation/drug effects, Cyclin A/metabolism, Cyclin-Dependent Kinase 2/metabolism, Cytochrome P-450 CYP1A1/genetics, Epithelial Cells/cytology/drug effects/metabolism, Fluorenes/toxicity, Gene Expression/drug effects, Hepatocytes/cytology/*drug effects/*metabolism, Messenger/genetics/metabolism, Multiprotein Complexes, Mutagens/toxicity, Mutation, Polycyclic Aromatic Hydrocarbons/*toxicity, Rats, Receptors, RNA, Small Interfering/genetics},

pubstate = {published},

tppubtype = {article}

}